TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Glaukos ( (GKOS) ).
Glaukos Corporation has announced its November 2025 Investor Presentation, highlighting its commitment to innovation in chronic eye disease treatments. The company emphasizes its strategic focus on commercial excellence and the development of groundbreaking therapies like the iDose TR, which aims to improve patient compliance and outcomes in glaucoma treatment. The presentation underscores Glaukos’s efforts to expand its market presence and enhance its product offerings, which could significantly impact its operations and industry positioning.
The most recent analyst rating on (GKOS) stock is a Hold with a $89.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
Glaukos’s overall score is driven by strong sales growth and positive future guidance, as highlighted in the earnings call. However, significant challenges in profitability, cash flow management, and valuation metrics weigh heavily on the score. Technical indicators suggest bearish momentum, further impacting the stock’s attractiveness.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos Corporation operates in the medical technology industry, focusing on innovative solutions for chronic eye diseases. The company offers products like micro-scale surgical devices, sustained-release pharmaceuticals, and bio-activated pharmaceuticals, targeting therapeutic areas such as glaucoma, keratoconus, and ocular cancer.
Average Trading Volume: 1,015,995
Technical Sentiment Signal: Sell
Current Market Cap: $4.82B
For detailed information about GKOS stock, go to TipRanks’ Stock Analysis page.